Latest:
Current Treatment Options for Patients with NSCLC
Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Mark H. O'Hara, MD
Latest:
Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer
Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.
Mark J. Levis, MD, PhD, Johns Hopkins University
Latest:
Combining and Sequencing FLT3 Inhibitors in AML
Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).
Mark J. Roschewski, MD
Latest:
Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt Lymphoma
Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.
Mark James Levis, MD, PhD
Latest:
Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AML
Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.